{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:34:18Z","timestamp":1793090058512,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Integrated analysis of genomes, transcriptomes, proteomes and drug responses of cancer cell lines (CCLs) is an emerging approach to uncover molecular mechanisms of drug action. We extend this paradigm to measuring proteome activity landscapes by acquiring and integrating quantitative data for 10,000 proteins and 55,000 phosphorylation sites (p-sites) from 125 CCLs. These data are used to contextualize proteins and p-sites and predict drug sensitivity. For example, we find that Progesterone Receptor (PGR) phosphorylation is associated with sensitivity to drugs modulating estrogen signaling such as Raloxifene. We also demonstrate that Adenylate kinase isoenzyme 1 (AK1) inactivates antimetabolites like Cytarabine. Consequently, high AK1 levels correlate with poor survival of Cytarabine-treated acute myeloid leukemia patients, qualifying AK1 as a patient stratification marker and possibly as a drug target. We provide an interactive web application termed ATLANTiC (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/atlantic.proteomics.wzw.tum.de\">http:\/\/atlantic.proteomics.wzw.tum.de<\/jats:ext-link>\n                    ), which enables the community to explore the thousands of novel functional associations generated by this work.\n                  <\/jats:p>","DOI":"10.1038\/s41467-020-17336-9","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T06:04:16Z","timestamp":1595225056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Proteome activity landscapes of tumor cell lines determine drug responses"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6651-1773","authenticated-orcid":false,"given":"Martin","family":"Frejno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9807-5825","authenticated-orcid":false,"given":"Benjamin","family":"Ruprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6408-3536","authenticated-orcid":false,"given":"Sebastian","family":"Scheich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-0252","authenticated-orcid":false,"given":"Karin","family":"Kleigrewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enken","family":"Drecoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6042-1585","authenticated-orcid":false,"given":"Patroklos","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0203-6803","authenticated-orcid":false,"given":"Alexander","family":"Hogrebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-2069","authenticated-orcid":false,"given":"Dominic","family":"Helm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4332-1280","authenticated-orcid":false,"given":"Julia","family":"Mergner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8767-6294","authenticated-orcid":false,"given":"Jana","family":"Zecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1066-6565","authenticated-orcid":false,"given":"Stephanie","family":"Heinzlmeir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9224-3258","authenticated-orcid":false,"given":"Mathias","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Dorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5450-4840","authenticated-orcid":false,"given":"Hans-Michael","family":"Kvasnicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilko","family":"Weichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9094-1677","authenticated-orcid":false,"given":"Bernhard","family":"Kuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"17336_CR1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740\u2013754 (2016).","journal-title":"Cell"},{"key":"17336_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.celrep.2015.03.050","volume":"11","author":"RT Lawrence","year":"2015","unstructured":"Lawrence, R. T. et al. The proteomic landscape of triple-negative breast cancer. Cell Rep. 11, 630\u2013644 (2015).","journal-title":"Cell Rep."},{"key":"17336_CR3","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.celrep.2017.08.010","volume":"20","author":"TI Roumeliotis","year":"2017","unstructured":"Roumeliotis, T. I. et al. Genomic determinants of protein abundance variation in colorectal cancer cells. Cell Rep. 20, 2201\u20132214 (2017).","journal-title":"Cell Rep."},{"key":"17336_CR4","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen, M. H. et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8, 935\u2013942 (2002).","journal-title":"Clin. Cancer Res."},{"key":"17336_CR5","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-13-3077","volume":"20","author":"SM Malik","year":"2014","unstructured":"Malik, S. M. et al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin. Cancer Res. 20, 2029\u20132034 (2014).","journal-title":"Clin. Cancer Res."},{"key":"17336_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.celrep.2013.07.018","volume":"4","author":"AM Gholami","year":"2013","unstructured":"Gholami, A. M. et al. Global proteome analysis of the NCI-60 cell line panel. Cell Rep. 4, 609\u2013620 (2013).","journal-title":"Cell Rep."},{"key":"17336_CR7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.15252\/msb.20177701","volume":"13","author":"M Frejno","year":"2017","unstructured":"Frejno, M. et al. Pharmacoproteomic characterisation of human colon and rectal cancer. Mol. Syst. Biol. 13, 951 (2017).","journal-title":"Mol. Syst. Biol."},{"key":"17336_CR8","doi-asserted-by":"publisher","first-page":"eaan4368","DOI":"10.1126\/science.aan4368","volume":"358","author":"S Klaeger","year":"2017","unstructured":"Klaeger, S. et al. The target landscape of clinical kinase drugs. Science 358, eaan4368 (2017).","journal-title":"Science"},{"key":"17336_CR9","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gkv1145","volume":"44","author":"JA Vizcaino","year":"2016","unstructured":"Vizcaino, J. A. et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 44, D447\u2013D456 (2016).","journal-title":"Nucleic Acids Res."},{"key":"17336_CR10","doi-asserted-by":"publisher","first-page":"D1271","DOI":"10.1093\/nar\/gkx1029","volume":"46","author":"T Schmidt","year":"2018","unstructured":"Schmidt, T. et al. ProteomicsDB. Nucleic Acids Res. 46, D1271\u2013D1281 (2018).","journal-title":"Nucleic Acids Res."},{"key":"17336_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-15-162","volume":"15","author":"C Meng","year":"2014","unstructured":"Meng, C., Kuster, B., Culhane, A. C. & Gholami, A. M. A multivariate approach to the integration of multi-omics datasets. BMC Bioinforma. 15, 162 (2014).","journal-title":"BMC Bioinforma."},{"key":"17336_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature18003","volume":"534","author":"P Mertins","year":"2016","unstructured":"Mertins, P. et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55\u201362 (2016).","journal-title":"Nature"},{"key":"17336_CR13","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan, T., Rindtorff, N. & Boutros, M. Wnt signaling in cancer. Oncogene 36, 1461\u20131473 (2017).","journal-title":"Oncogene"},{"key":"17336_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","volume":"45","author":"CB Lozzio","year":"1975","unstructured":"Lozzio, C. B. & Lozzio, B. B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45, 321\u2013334 (1975).","journal-title":"Blood"},{"key":"17336_CR15","first-page":"142","volume":"10","author":"WG Dirks","year":"1996","unstructured":"Dirks, W. G. et al. The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines. Leukemia 10, 142\u2013149 (1996).","journal-title":"Leukemia"},{"key":"17336_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8002","volume":"6","author":"E Medico","year":"2015","unstructured":"Medico, E. et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat. Commun. 6, 7002 (2015).","journal-title":"Nat. Commun."},{"key":"17336_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinforma. 9, 559 (2008).","journal-title":"BMC Bioinforma."},{"key":"17336_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 14, 7 (2013).","journal-title":"BMC Bioinforma."},{"key":"17336_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrm1907","volume":"7","author":"J Jiricny","year":"2006","unstructured":"Jiricny, J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 7, 335\u2013346 (2006).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"17336_CR20","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/sj.ejhg.5201858","volume":"15","author":"A Alemayehu","year":"2007","unstructured":"Alemayehu, A. & Fridrichova, I. The MRE11\/RAD50\/NBS1 complex destabilization in Lynch-syndrome patients. Eur. J. Hum. Genet. 15, 922\u2013929 (2007).","journal-title":"Eur. J. Hum. Genet."},{"key":"17336_CR21","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1038\/s41388-018-0196-1","volume":"37","author":"J Tang","year":"2018","unstructured":"Tang, J. et al. DEAD-box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival in CRC patients. Oncogene 37, 3006\u20133021 (2018).","journal-title":"Oncogene"},{"key":"17336_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nature08966","volume":"465","author":"JC Scheuermann","year":"2010","unstructured":"Scheuermann, J. C. et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465, 243\u2013247 (2010).","journal-title":"Nature"},{"key":"17336_CR23","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.1038\/sj.onc.1210419","volume":"26","author":"C Miquel","year":"2007","unstructured":"Miquel, C. et al. Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene 26, 5919\u20135926 (2007).","journal-title":"Oncogene"},{"key":"17336_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren, R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5, 172\u2013183 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"17336_CR25","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-12-1370","volume":"72","author":"WC Reinhold","year":"2012","unstructured":"Reinhold, W. C. et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 72, 3499\u20133511 (2012).","journal-title":"Cancer Res."},{"key":"17336_CR26","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1038\/sj.onc.1203620","volume":"19","author":"A Follenzi","year":"2000","unstructured":"Follenzi, A. et al. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19, 3041\u20133049 (2000).","journal-title":"Oncogene"},{"key":"17336_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1006\/geno.2001.6678","volume":"79","author":"DK Kim","year":"2002","unstructured":"Kim, D. K. et al. The human T-type amino acid transporter-1: characterization, gene organization, and chromosomal location. Genomics 79, 95\u2013103 (2002).","journal-title":"Genomics"},{"key":"17336_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"17336_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.molcel.2018.01.012","volume":"69","author":"J Murai","year":"2018","unstructured":"Murai, J. et al. SLFN11 blocks stressed replication forks independently of ATR. Mol. Cell 69, 371\u2013384 e376 (2018).","journal-title":"Mol. Cell"},{"key":"17336_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.clcc.2013.07.001","volume":"12","author":"A Strimpakos","year":"2013","unstructured":"Strimpakos, A. et al. The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. Clin. Colorectal Cancer 12, 267\u2013274 e262 (2013).","journal-title":"Clin. Colorectal Cancer"},{"key":"17336_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0378-4347(85)80007-4","volume":"337","author":"RB Schilcher","year":"1985","unstructured":"Schilcher, R. B., Young, J. D. & Baker, L. H. Reversed-phase high-performance liquid chromatographic determination of tricyclic nucleoside and tricyclic nucleoside 5\u2032-phosphate in biological specimens. J. Chromatogr. 337, 55\u201362 (1985).","journal-title":"J. Chromatogr."},{"key":"17336_CR32","first-page":"491","volume":"70","author":"LL Wotring","year":"1986","unstructured":"Wotring, L. L., Crabtree, G. W., Edwards, N. L., Parks, R. E. Jr. & Townsend, L. B. Mechanism of activation of triciribine phosphate (TCN-P) as a prodrug form of TCN. Cancer Treat. Rep. 70, 491\u2013497 (1986).","journal-title":"Cancer Treat. Rep."},{"key":"17336_CR33","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1126\/science.1232044","volume":"340","author":"L Bar-Peled","year":"2013","unstructured":"Bar-Peled, L. et al. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 340, 1100\u20131106 (2013).","journal-title":"Science"},{"key":"17336_CR34","doi-asserted-by":"publisher","first-page":"196ra198","DOI":"10.1126\/scitranslmed.3005753","volume":"5","author":"RB Corcoran","year":"2013","unstructured":"Corcoran, R. B. et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci. Transl. Med. 5, 196ra198 (2013).","journal-title":"Sci. Transl. Med."},{"key":"17336_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","volume":"66","author":"R Roskoski Jr.","year":"2012","unstructured":"Roskoski, R. Jr. ERK1\/2 MAP kinases: structure, function, and regulation. Pharm. Res. 66, 105\u2013143 (2012).","journal-title":"Pharm. Res."},{"key":"17336_CR36","doi-asserted-by":"publisher","first-page":"995","DOI":"10.15252\/embj.201695534","volume":"36","author":"CW Pan","year":"2017","unstructured":"Pan, C. W. et al. AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction. EMBO J. 36, 995\u20131010 (2017).","journal-title":"EMBO J."},{"key":"17336_CR37","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","volume":"18","author":"J Villanueva","year":"2010","unstructured":"Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K. Cancer Cell 18, 683\u2013695 (2010).","journal-title":"Cancer Cell"},{"key":"17336_CR38","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1158\/1535-7163.MCT-11-0534","volume":"10","author":"N Berdelle","year":"2011","unstructured":"Berdelle, N., Nikolova, T., Quiros, S., Efferth, T. & Kaina, B. Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM\/ATR damage response in cancer cells. Mol. Cancer Ther. 10, 2224\u20132233 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"17336_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11306-014-0698-y","volume":"11","author":"\u0130 Karaman","year":"2015","unstructured":"Karaman, \u0130. et al. Sparse multi-block PLSR for biomarker discovery when integrating data from LC\u2013MS and NMR metabolomics. Metabolomics 11, 367\u2013379 (2015).","journal-title":"Metabolomics"},{"key":"17336_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1101\/gad.1352206","volume":"20","author":"D Kashatus","year":"2006","unstructured":"Kashatus, D., Cogswell, P. & Baldwin, A. S. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev. 20, 225\u2013235 (2006).","journal-title":"Genes Dev."},{"key":"17336_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7007-2-24","volume":"2","author":"DR Mattoon","year":"2004","unstructured":"Mattoon, D. R., Lamothe, B., Lax, I. & Schlessinger, J. The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K\/Akt cell survival pathway. BMC Biol. 2, 24 (2004).","journal-title":"BMC Biol."},{"key":"17336_CR42","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/humu.23175","volume":"38","author":"L Pannone","year":"2017","unstructured":"Pannone, L. et al. Structural, functional, and clinical characterization of a novel PTPN11 mutation cluster underlying Noonan syndrome. Hum. Mutat. 38, 451\u2013459 (2017).","journal-title":"Hum. Mutat."},{"key":"17336_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02354-x","volume":"9","author":"S Han","year":"2018","unstructured":"Han, S. et al. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma. Nat. Commun. 9, 28 (2018).","journal-title":"Nat. Commun."},{"key":"17336_CR44","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1634\/theoncologist.5-5-388","volume":"5","author":"DB Muchmore","year":"2000","unstructured":"Muchmore, D. B. Raloxifene: a selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist 5, 388\u2013392 (2000).","journal-title":"Oncologist"},{"key":"17336_CR45","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1158\/0008-5472.CAN-17-1327","volume":"78","author":"Y Wu","year":"2018","unstructured":"Wu, Y. et al. Tamoxifen resistance in breast cancer is regulated by the EZH2-ERalpha-GREB1 transcriptional axis. Cancer Res. 78, 671\u2013684 (2018).","journal-title":"Cancer Res."},{"key":"17336_CR46","doi-asserted-by":"publisher","first-page":"13308","DOI":"10.1074\/jbc.271.23.13308","volume":"271","author":"GS Takimoto","year":"1996","unstructured":"Takimoto, G. S. et al. Role of phosphorylation on DNA binding and transcriptional functions of human progesterone receptors. J. Biol. Chem. 271, 13308\u201313316 (1996).","journal-title":"J. Biol. Chem."},{"key":"17336_CR47","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative G. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N. Engl. J. Med. 319, 1681\u20131692 (1988).","DOI":"10.1056\/NEJM198812293192601"},{"key":"17336_CR48","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1042\/BJ20101443","volume":"433","author":"C Panayiotou","year":"2011","unstructured":"Panayiotou, C., Solaroli, N., Xu, Y., Johansson, M. & Karlsson, A. The characterization of human adenylate kinases 7 and 8 demonstrates differences in kinetic parameters and structural organization among the family of adenylate kinase isoenzymes. Biochem. J. 433, 527\u2013534 (2011).","journal-title":"Biochem. J."},{"key":"17336_CR49","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.biocel.2013.02.004","volume":"45","author":"M Amiri","year":"2013","unstructured":"Amiri, M., Conserva, F., Panayiotou, C., Karlsson, A. & Solaroli, N. The human adenylate kinase 9 is a nucleoside mono- and diphosphate kinase. Int. J. Biochem. Cell Biol. 45, 925\u2013931 (2013).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"17336_CR50","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nm.4255","volume":"23","author":"C Schneider","year":"2017","unstructured":"Schneider, C. et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat. Med. 23, 250\u2013255 (2017).","journal-title":"Nat. Med."},{"key":"17336_CR51","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.7717\/peerj-cs.67","volume":"2","author":"J Anaya","year":"2016","unstructured":"Anaya, J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput. Sci. 2, e67 (2016).","journal-title":"PeerJ Comput. Sci."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17336-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17336-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17336-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T19:11:33Z","timestamp":1670267493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-17336-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["17336"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-17336-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]},"assertion":[{"value":"31 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.W. and B.K. are founders and shareholders of OmicScouts GmbH and msAId GmbH. They have no operational role in these companies. M.F. is a founder, shareholder and the CEO of msAId GmbH. The work presented here was not in any way related to these affiliations. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3639"}}